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Objective: To study temporomandibular joint (TMJ) involvement in an autoimmune murine model of
rheumatoid arthritis (RA), a disease characterized by inﬂammatory destruction of the synovial joints.
Although TMJ dysfunction is frequently found in RA, TMJ involvement in RA remains unclear, and TMJ
pathology has not been studied in systemic autoimmune animal models of RA.
Methods: Proteoglycan (PG) aggrecan-induced arthritis (PGIA) was generated in genetically susceptible
BALB/c mice. TMJs and joint tissues/cartilage were harvested for histological and immunohistochemical
analyses and RNA isolation for quantitative polymerase chain-reaction. Serum cytokine levels were
measured in mice with acute or chronic arthritis, and in non-arthritic control animals.
Results: Despite the development of destructive synovitis in the limbs, little or no synovial inﬂammation
was found in the TMJs of mice with PGIA. However, the TMJs of arthritic mice showed evidence of
aggrecanase- and matrix metalloproteinase-mediated loss of glycosaminoglycan-containing aggrecan,
and in the most severe cases, structural damage of cartilage. Serum levels of pro-inﬂammatory cytokines,
including interleukin (IL)-1b, were elevated in arthritic animals. Expression of the IL-1b gene was also
high in the inﬂamed limbs, but essentially normal in the TMJs. Local expression of genes encoding
matrix-degrading enzymes (aggrecanases and stromelysin) was upregulated to a similar degree in both
the limbs and the TMJs.
Conclusion: We propose that constantly elevated levels of catabolic cytokines, such as IL-1b, in the
circulation (released from inﬂamed joints) create a pro-inﬂammatory milieu within the TMJ, causing
local upregulation of proteolytic enzymes and subsequent loss of aggrecan from cartilage.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune joint
disease affecting 1% of the human population. The disease starts
with synovial inﬂammation in the peripheral joints, which ulti-
mately leads to destruction of articular cartilage and complete loss
of joint function1,2. Several animal models mimic one or more
characteristics of the human disease. Cartilage proteoglycan (PG)-
induced arthritis (PGIA) in BALB/c mice shares many similaritiesto: K. Mikecz, Section of
gery and Biochemistry, Rush
ite 708, 1735 W. Harrison Str.,
942-8828.
z).
s Research Society International. Pwith RA, as indicated by genetic studies, clinical assessments,
laboratory tests (presence of serum cytokines and autoantibodies,
including rheumatoid factor and anti-citrullinated protein anti-
bodies), X-rays and histopathology of diarthrodial joints3. Like RA,
PGIA is a progressive joint disease, where the number of arthritic
joints increases over time, and the affected joints ultimately
become deformed due to loss of cartilage and erosion of bone4.
The temporomandibular joint (TMJ) is a synovial joint, in which
the joint space is divided by a ﬁbrocartilaginous disc (meniscus).
TMJ dysfunction, which is relatively common in humans, is most
frequently caused by meniscus displacement (internal derange-
ment disorder) or is associated with the development of osteoar-
thritis (OA)-like degenerative changes of articular cartilage
covering the mandibular condyle (reviewed in5,6). The estimated
frequency of TMJ involvement in patients with RA ranges from 4%
to 86% depending on the patient selection and methods used forublished by Elsevier Ltd. All rights reserved.
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different from those of arthritic joints, but very limited information
is available about the histopathology of the TMJ in RA. One study
reported complete replacement of cartilage by ﬁbrous tissue in
advanced RA10, and another described inﬂammatory and degen-
erative changes in the RA TMJ synovium obtained from arthroscopy
material not containing cartilage11. The paucity of information
regarding cartilage histopathology makes it uncertain whether TMJ
involvement in RA is inﬂammatory or degenerative in nature.
Animal models have been developed to study the response of
TMJ to inﬂammatory insults; however, in these models, the
inﬂammation-inducing compounds, such as adjuvant or antigen,
are injected directly into the TMJ12,13. TMJ involvement has not
been studied in any of the systemic autoimmune animal models of
RA, such as PGIA. Therefore, the goal of the present work was to
identify pathologic changes in the TMJ in the context of arthritis
development and progression in mice with PGIA.Materials and methods
Antigen, animals, immunization, and assessment of peripheral
arthritis
The collection of cartilage from consenting patients undergoing
total joint replacements was approved by the Institutional Review
Board of RushUniversityMedical Center (Chicago, IL). PG (aggrecan)
was extracted from cartilage and puriﬁed as described4. Female
BALB/c mice (12e16 weeks old) were purchased from Charles River
Laboratories (Kingston Colony). Animals were immunized intra-
peritoneally with an emulsion of PG (100 mg of protein in 100 ml
phosphate-buffered saline, PBS) and 2 mg dimethyl dioctadecyl-
ammoniumbromide (DDA) adjuvant (SigmaeAldrich, St. Louis,MO)
on days 0, 21, and 424. Controlmice received an emulsion of PBS and
DDA (without antigen) under the same schedule. All animal
procedures were conducted under a protocol approved by the
Institutional Animal Care and Use Committee of Rush University
Medical Center. Immunized mice were examined 2e3 times a week
for clinical symptoms of arthritis after the second immunization.
The time of onset and incidence of arthritis were recorded, and
severity was scored based upon swelling and redness of each paw
on a scale ranging from 0 to 4, yielding a potential maximum
severity score of 16 per mouse4,14. Mice assigned to the “acute”
group (N¼ 10) were sacriﬁced during the clinically determined
acute phase of PGIA (see Fig. 1A, dotted-line arrow), i.e., 6e7 days35 38
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Fig. 1. Incidence and severity of PGIA in BALB/c mice used in this study. (A) Arthritis inciden
injected, N¼ 22) or adjuvant (PBS/DDA)-injected (N¼ 8) mice. Thick solid arrow points to
clinically determined acute and chronic phases of arthritis are indicated by dotted-line an
groups of mice with acute (N¼ 10) and chronic (N¼ 12) arthritis, and non-arthritic contro
a cumulative inﬂammation score. The data shown are the means (incidence) or the meansafter the onset of arthritis, when swelling and rednesswere steadily
increasing in the distal joints of the limbs. The “chronic” group
(N¼ 12) was sacriﬁced during the chronic phase of the disease
(Fig. 1A, dashed-line arrow), i.e., approximately 2 weeks after the
onset of arthritis (day 60 after the ﬁrst PG/DDA injection), when
swelling was still present, but hardening of periarticular soft tissue,
joint deformities and ankylosis dominated the clinical picture3,14.
PBS/DDA-injected (non-arthritic) control mice (N¼ 8) were sacri-
ﬁced with the chronic group on day 60.
Measurement of cytokines in serum
Blood was collected from control (PBS/DDA-injected) and
arthritic mice at the time of sacriﬁce. Concentrations of pro-
inﬂammatory cytokines, including interleukin (IL)-1b, tumor
necrosis factor (TNF)a, IL-6, and IL-17, in serum were measured
using capture enzyme-linked immunosorbent assays (ELISA)
according to the manufacturers’ instructions (BD Biosciences, San
Diego, CA, or R&D Systems, Minneapolis, MN). Results were
expressed as picograms (pg) of cytokine per ml serum.
Histology, histochemistry, and immunohistochemistry (IHC)
Hind limbs and heads were dissected from euthanized mice on
day 49 or 50 (for mice with acute arthritis of peripheral joints) and
from mice in the chronic arthritis and control groups on day 60.
Headswere cut in half in the sagittal direction before ﬁxation in 10%
neutral buffered formalin (Protocol Formalin, Fisher Scientiﬁc,
Kalamazoo, MI). Both the limbs and heads were acid-decalciﬁed
and embedded in parafﬁn. The heads were carefully oriented in the
parafﬁn blocks so that the sectioning blade could run parallel to the
posterior mandible and the mandibular head. Deparafﬁnized
sagittal serial sections (6e8 mm thick) of paws and TMJs were
stained with hematoxylin and eosin (Sigma) to evaluate structural
integrity, or with safranin O and fast green (Acros Organics, NJ) to
assess cartilage PG aggrecan loss15, using standard histochemical
methods described earlier16. Sections from all experimental groups
were stained simultaneously. For IHC, deparafﬁnized sections were
rehydrated in 50 mM Tris-acetate buffer (pH 7.4). To unmask the
protein epitopes in cartilage, the sections were digested with
0.5 units/ml chondroitinase ABC (Seikagaku Corp., Japan) dissolved
in 50 mM Tris-acetate buffer for 60 min16. Non-speciﬁc protein
binding sites were blocked with 10% normal goat serum in PBS and
then stained with rabbit antibodies speciﬁc to cartilage PG0
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neoepitopes-VDIPEN341 and -NVTEGE373 (NITEGE in human) as
described16. Neoepitope-VIDIPEN is generated mostly by strome-
lysin (matrix metalloproteinase [MMP]-3) by cleaving the inter-
globular domain (IGD) of the core protein of cartilage PG aggrecan.
NITEGE/NVTEGE is another cleavage product of the IGD by aggre-
canase-1 (also known as a disintegrin and metalloproteinase with
thrombospondin type 1 motif-4, ADAMTS-4), or aggrecanase-2
(ADAMTS-5)17,18. After the cleavage of the IGD of aggrecan by these
enzymes, the neoepitopes (bound to hyaluronan via the G1
domain) become available for the respective antibodies16,17. The
core protein released by the enzymes (the rest of the PG molecule),
with negatively charged glycosaminoglycan (GAG) side chains,
diffuses out of the cartilage. As a result, the negatively charged
GAGs, stained red with safranin O15, are lost. The rabbit antibodies
were used at a 1:40 dilution, and the binding of the primary anti-
bodies was detected with peroxidase-conjugated goat anti-rabbit
IgG (Invitrogen, Carlsbad, CA). Digestion with chondroitinase ABC
was sufﬁcient for these antibodies to access the epitopes in the
parafﬁn sections, and no antigen retrieval was necessary. Peroxi-
dase reactions were developed with diaminobenzidine (DAB)
chromogen and H2O2 substrate (Vector Laboratories, Burlingame,
CA) as described16. All slides were exposed to DAB for the same
length of time, and the speciﬁcity of immunostaining was ensured
by replacement of the ﬁrst antibodies with normal rabbit serum in
one set of slides. All tissue sections were viewed under a Nikon
Microphot-FXA (Nikon, Melville, NY) bright-ﬁeld microscope. TIF
images (in 24-bit color RGBmode) were generated using MetaView
image acquisition software (Molecular Devices, Sunnyvale, CA).
Morphometric analysis of safranin O and IHC staining
Morphometric analyses of the densities of safranin O staining
and IHC (DAB staining) were performed by a blinded investigator,
using a modiﬁed version of a previously published Adobe Photo-
shop-based protocol for quantitative image analysis19. In brief, TIF
images of tissue sections were opened in Adobe Photoshop (version
6, Adobe Systems, San Jose, CA), and three rectangular areas (cor-
responding to full-thickness cartilage in the middle and two lateral
regions of the mandibular or distal tibial cartilage) were selected
from each section. Using the “magic wand” tool, a small group of
pixels of positive staining (red for safranin O, and dark brown for
DAB staining, respectively) was selected within each area. Using
“Similar” under the Selection command, the pixels were extended
to regions containing color pixels of similar intensity. The data of the
image histogram (mean intensity and pixel number of the selected
color) were exported to Microsoft Excel. The image was then con-
verted to grayscale, and the gray pixel values of the histogram of the
entireﬁeld (total pixels)were also exported to Excel. The percentage
of pixels of positive staining, relative to the total pixels of each area,
was calculated by dividing the selected color pixels by the total
(gray) pixels of the entire area, and then multiplying by 100.
Quantitative comparison of positively stained areas of control and
arthritic specimens was carried out using the same main color
intensity values for all tissue sections stainedwith the same reagent.
Average of data from left-side and right-side joints from the same
mouse was handled as a single value from a single animal.
Quantitative real-time polymerase chain-reaction (QRT-PCR)
To isolate RNA,mandibular cartilage and adjacent synovial tissue
(ST) (without bone) were dissected from euthanized animals
(experimental groups similar to those shown in Fig. 1) under
a preparative stereomicroscope in RNAse-free conditions. The tissue
pieces were collected in RNALater solution and homogenized in TRIReagent (SigmaeAldrich). Tissue samples from at least two animals
(4e6 TMJs)/group (non-arthritic controls, micewith acute PGIA and
mice with chronic PGIA) were pooled, and RNA was isolated from
three independent pools. RNA was also isolated similarly from
normal and inﬂamed paw homogenates, which contained cartilage
and soft tissue dissected from the ankle and mid-foot area, but not
bone. The quality of RNA samples was determined using an Agilent
2100 Bioanalyzer (Agilent Technologies, Foster City, CA). High
quality samples were used in reverse transcription reactions. cDNAs
were synthesized using an oligo-dT reverse primer and the Super-
Script First Strand Synthesis kit (Invitrogen, Carlsbad, CA). QRT-PCR
was carried out with the iQ5 real-time PCR detection system
(Bio-Rad, Hercules, CA). Gene-speciﬁc PCR primers and FAM-labeled
TaqMan probes for mouse IL-1b, stromelysin [MMP-3], ADAMTS-4
and ADAMTS-5 were purchased from Applied Biosystems (Foster
City, CA). TaqMan gene expression assayswere carried out according
to the manufacturer’s instructions (Applied Biosystems). QRT-PCR
data were analyzed with the iQ5 system’s software package.
Expression of the GAPDHhousekeeping genewas used to normalize
the data within each pooled sample. Quantiﬁcation of gene
expression among pooled samples (relative to control) was done
employing the 2DDCT method20, and results were expressed as fold
changes relative to the corresponding control samples.
Statistical analyses
Statistical analyseswere performedusing SPSS software (version
16; SPSS Inc., Chicago, IL). Descriptive statistics were used to deter-
mine group means and 95% conﬁdence intervals (mean CI 95%).
Statistically signiﬁcant differences among the groups were assessed
using analysis of variance (ANOVA) with post-hoc Dunnett’s t test.
A P value of <0.05 was considered statistically signiﬁcant.
Results
We investigated TMJ involvement in PGIA at the acute (10 mice)
and subacute/chronic (12 mice) phases of peripheral joint inﬂam-
mation compared with age-matched, (eight PBS/DDA-injected)
non-arthritic, control animals. Arthritis developed after the third
injection of PG in DDA [Fig.1 (A, thick solid arrow)]. This initial acute
phase [Fig.1 (A, dotted-line arrow)]was characterized by increasing
swelling and redness of the paws. Approximately 10 days after
arthritis onset (wday 52 of immunization), the animals entered the
chronic phase of PGIA [Fig. 1(A), dashed-line arrow], characterized
by hardening of the periarticular soft tissue, deformities and
ankylosis3,14. By the end of the experimental period (day 60), 11 of
the 12 remaining PG-immunized animals had chronic arthritis
involving the limbs, while none of the control animals showed any
signs of joint disease [Fig. 1(AeB)]. To monitor the progression of
inﬂammation or cartilage destruction in the TMJs (if any), micewith
acute and chronic arthritis were sacriﬁced on days 49e50 and day
60, respectively [Fig. 1 (A, thin solid arrows)], and their TMJs and
ankle joints were compared with each other or with the corre-
sponding tissues of non-arthritic control mice. Figure 2(A) and (B)
shows representative examples of hematoxylin-eosin-stained
histological sections prepared from the ankle joints of control and
arthritic animals sacriﬁced on day 60. The ankle joints of the control
mice did not exhibit any signs of structural damage [Fig. 2(A)], but
inﬂammatory cell inﬁltration of the STandmassive joint destruction
were evident in the ankles of the PG-immunized animals [Fig. 2(B)].
To determine the extent of inﬂammation-induced loss of cartilage
aggrecan, we stained adjacent sections of the ankle joints of normal
and arthritic micewith safranin O and fast green. Safranin O detects
the negatively chargedGAG side chains of aggrecan in cartilage15. As
a result, the extent of red staining is proportional to the amount of
Fig. 2. Histochemical and immunohistochemical features of the limb (ankle) joints and TMJ in mice with PGIA. (A) A hematoxylin-eosin-stained tissue section from the ankle (tibio-
tarsal) joint from a PBS/DDA-injected control mouse shows normal structure. The articular cartilage surface is smooth, and the ST is free of inﬂammatory cell inﬁltrates. (A1) The
articular cartilage of the distal tibia (section adjacent to the boxed area in (A) shows strong and fairly even staining with safranin O (red), but (A2) negligible immunostaining for
aggrecan neoepitopes with anti-NITEGE antibody (or anti-VDIPEN; not shown). (B) The ankle joint from a mouse with chronic arthritis shows massive inﬁltration of ST by
leukocytes and loss of superﬁcial zone chondrocytes at the joint margins where inﬂammatory cells are in contact with cartilage (also known as “pitting”; depicted here by
arrowheads). Bone erosion by the invasive synovium is also evident (arrow). (B1) The cartilage of distal tibia shows generalized loss of safranin O staining, associated with (B2)
strong positive immunostaining for aggrecan neoepitopes (anti-NITEGE is shown). (C) Normal TMJ structure from the control mouse. (D) The TMJ of the mouse with chronic PGIA
(ankle shown in B). The TMJ does not exhibit severe structural damage, except for the lighter staining of the mandibular cartilage than the control TMJ, and a few ﬁssures at the
cartilage margin (arrows). A small collection of inﬂammatory cells is also present in the synovium (box and insert at 6 magniﬁcation). (E) The cartilage of the normal TMJ shows
strong and homogenous staining with safranin O (red), which indicates intact aggrecan content. (F) Safranin O staining is weak and restricted to a few chondrocytes in the TMJ
cartilage of a mouse with chronic PGIA. The cartilage also shows evidence of structural damage (ﬁssures) and chondrocyte clustering (boxed area, magniﬁed in H). (G) Adjacent
sections of the control TMJ were stained with safranin O (left-hand panel) and with antibodies against the aggrecan neoepitopes -NITEGE (middle panel) and -VDIPEN (right-hand
panel). Weak positive staining for both neoepitopes is visible around some chondrocytes. (H) The area of the TMJ from the arthritic mouse that stains weakly with safranin O (left-
hand panel) shows strong immunostaining for both -NITEGE and -VDIPEN neoepitopes (middle and right-hand panels, respectively).
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of the distal tibia of the control mouse showed intense red staining
with safranin O [Fig. 2 (A1)], whereas very little red staining was
seen in the tibial cartilage of the mouse with chronic arthritis in the
ankle joint [Fig. 2 (B1)]. Considering that the loss of GAG-decorated
aggrecan fragments from cartilage is the result of cleavage of thecore protein by aggrecanases (ADAMTS-4 and ADAMTS-5) or stro-
melysin (MMP-3)17,21, we sought to determine whether the aggre-
can neoepitopes generated by ADAMTSs or MMP-3 (-NITEGE and
-VDIPEN, respectively) were detectable in the cartilage of arthritic
ankles. As compared to the normal cartilage, which showed
essentially negligible immunostaining with the anti-NITEGE
S. Ghassemi-Nejad et al. / Osteoarthritis and Cartilage 19 (2011) 458e465462antibody [Fig. 2 (A2)], staining for this aggrecan neoepitope was
very strong in the cartilage of arthritic ankle [Fig. 2 (B2)]. Similar
differences were observed when sections of control and arthritic
ankle joints were reacted with the anti-VDIPEN antibody [Table I
and results not shown].
When hematoxylin-eosin-stained sections of the TMJs from
control and arthritic mice were compared, the most notable
differencewas the diminished basophilic staining in themandibular
cartilage of arthriticmice [Fig. 2(C) and (D)]. In themost severe cases
of chronic PGIA, there was structural evidence of cartilage damage
(ﬁbrillation or ﬁssures) in the TMJ [Fig. 2 (D, arrows), or small
collections of inﬂammatory cells could be seen in the TMJ synovium
[Fig. 2 (D, insert)]. To determine if the apparent loss of hematoxylin
staining from the TMJ cartilage of the arthritic mouse could reﬂect
a loss of aggrecan, we stained adjacent sections of the corre-
sponding TMJs with safranin O and fast green. Indeed, the control
TMJ cartilage showed strong and nearly homogenous staining with
safranin O [Fig. 2(E) and (G)] whereas signiﬁcant loss of red staining
was observed in the TMJ of the arthritic mouse [Fig. 2(F) and (H)]. In
the latter case, safranin O staining was mainly found around the
chondrocytes and was absent from the inter-territorial matrix. In
addition, the chondrocytes appeared to form clusters in the TMJ of
the arthritic mouse [Fig. 2(H)]. Immunostaining for aggrecan neo-
epitopes revealed light staining for both -NITEGE and -VDIPEN
around some of the chondrocytes in the healthy TMJ [Fig. 2 (G,
middle and right-side panels, respectively)], which is consistent
with thenormal turnover of aggrecan in the cartilage. In comparison
with the control mice, immunostaining for -NITEGE and -VDIPEN
was very strong in the TMJ cartilage of the arthritic mouse [Fig. 2
(H)], which indicated that aggrecan fragments were generated
more extensively in the TMJ of the mouse affected with peripheral
joint inﬂammation than in the one without arthritis.
While the presence of inﬂammatory cells in the TMJs was not
typical, diminished safranin O staining and enhanced aggrecan
neoepitope immunostainingwas found in the TMJs of most animals
at the chronic phase of PGIA and in a few TMJs in the acute arthritic
group. To quantitatively assess the extent of aggrecan degradation
in the different joints, we performed morphometric analyses of
safranin O staining and IHC (anti-NITEGE and anti-VDIPEN) reac-
tions using tissue sections from the TMJs and ankle joints of control
mice and of animals with acute and chronic PGIA. As shown in
Table I, neither safranin O staining nor immunostaining for the
NITEGE neoepitope in the TMJ cartilage was signiﬁcantly different
between normal mice and those with acute PGIA, but the differ-
ences became statistically signiﬁcant after the mice reached theTable I
Quantitative analysis of Safranin O staining of GAGs and immunohistochemical staining o
in mice with acute or chronic PGIA and in non-arthritic controls
Joint/staining (% positive) Control (N¼ 8) Acute PGIA (N¼ 10) P (acute vs c
TMJ/Safranin O
Mean (CI 95%) 54.2 (46.2e62.2) 49.1 (43.0e55.2) 0.1911
Ankle/Safranin O
Mean (CI 95%) 47.9 (40.6e55.2) 12.6 (9.3e15.9) 0.0033
TMJ/NITEGE
Mean (CI 95%) 2.1 (1.6e2.6) 2.6 (1.8e3.4) 0.2565
Ankle/NITEGE
Mean (CI 95%) 0.7 (0.3e1.1) 15.5 (11.7e19.3) 0.0016
TMJ/VDIPEN
Mean (CI 95%) 0.5 (0.2e0.8) 1.1 (0.6e1.6) 0.0450
Ankle/VDIPEN
Mean (CI 95%) 0.7 (0.2e1.2) N.D.
The percent of positively stained area (% positive) within each TMJ or ankle cartilage sect
described in the Methods. The values shown are the means and 95% CI. Statistically sig
determined.chronic phase of PGIA. In the arthritic ankle joints, aggrecan
degradation (diminished safranin O staining and generation of
NITEGE neoepitope) was signiﬁcantly greater than in the controls
already at the acute phase of PGIA, and progressed further in
chronic disease [Table I]. These results suggested that aggrecan
degradation occurred in both the ankles and the TMJs in PGIA, but
was more progressive in the ankles than in the TMJs.
The presence of very little or no synovial inﬂammation coupled
with massive loss of aggrecan is one of the typical features of OA22.
Pro-inﬂammatory cytokines, such as IL-1b, TNFa, IL-6, or IL-17, have
been implicated in the initiationofmatrix breakdown incartilage22,23.
Among these cytokines, IL-1b, which can also be produced by the
chondrocytes themselves in OA, is thought to be the main effector of
aggrecan breakdown via induction of aggrecanase and MMP expres-
sion in the chondrocytes23. We found evidence of upregulated
expression of the genes encoding ADAMTS-4, ADAMTS-5 andMMP-3
(w20-fold,w7-fold, andw18-fold increases, respectively, relative to
normal controls) in the TMJs of animals with both acute and chronic
PGIA [Fig. 3(AeC)], but the IL-1b gene was not upregulated (only
w1.5-fold higher than control) in these TMJ samples [Fig. 3(D)]. The
expression levels of aggrecanases and MMP-3 in the arthritic
peripheral joints increased as inﬂammation progressed [Fig. 3(EeG)],
but the overallmagnitude of gene expressionwas similar to the levels
found in the TMJs, except for ADAMTS-5, which was expressed at
slightly lower levels in the arthritic ankle joints. In contrast, the IL-1b
genewashighlyover-expressed in the arthritic limbsat both the acute
and the chronic phases of PGIA relative to the normal control,
although therewas a statistically signiﬁcant decrease in expression as
arthritis progressed into the chronic phase [Fig. 3(H)]. This latter
observation suggested that the inﬂamed limb joints were the major
sources of the “catabolic” cytokine IL-1b.
In order to act on the TMJ cartilage at an area that is distant from
the sites of production, IL-1b has to be present in the circulation.
Indeed, while IL-1b was not detectable in the sera of control
animals, it was present in the sera of mice with either acute or
chronic PGIA [Table II]. Moreover, additional pro-inﬂammatory
cytokines, such as TNFa, IL-6, and IL-17, all of which could also
contribute to cartilage matrix breakdown22, were detected in the
sera of arthritic animals at both the acute and chronic phases of
PGIA [Table II].
Discussion
This is the ﬁrst study to demonstrate that degenerative changes
develop in the mandibular cartilage of the TMJs of mice during thef aggrecan neoepitopes (NITEGE and VDIPEN) of the cartilage of TMJ and ankle joints
ontrol) Chronic PGIA (N¼ 11) P (chronic vs control) P (chronic vs acute)
6.4 (4.5e8.3) 0.0014 0.0027
1.9 (1.0e2.8) 0.0001 0.0079
16.7 (13.2e20.2) 0.0299 0.0357
26.3 (22.2e30.4) 0.0004 0.0425
13.9 (10.3e17.5) 0.0001 0.0003
19.0 (14.7e23.3) 0.0001
ion was quantitatively determined using Adobe Photoshop-based image analysis, as
niﬁcant differences (P< 0.05) are indicated in italics. N: number of mice; N.D.: not
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Fig. 3. Expression of genes encoding matrix-degrading enzymes and IL-1b in the TMJs and ankle joints of mice with PGIA. QRT-PCR was employed to compare the expression levels
of these genes between control and arthritic mice in the TMJs (AeD) and the ankle joints (EeH) in PGIA. The results are from three independent experiments (N¼ 3), using RNA of
cartilage and ST (pooled from the joints of 2e3 mice/group), and are expressed as fold change (increase) in expression level relative to the control (mean 95% CI). For comparison
of the magnitude of gene upregulation, the control levels are indicated by horizontal dotted lines. Statistically signiﬁcant differences (P< 0.05) between “acute” and “chronic” PGIA
samples are depicted by asterisks and the P values are indicated. (A) The gene encoding the aggrecanase ADAMTS-4 was upregulated in the TMJs of mice with both acute (crossed
bars) and chronic (black bars) arthritis compared to TMJs of non-arthritic mice (dashed line). (B) The aggrecanase ADAMTS-5 was also upregulated, but to a lesser extent. (C) Over-
expression of MMP-3 (stromelysin) was also detected in the PGIA samples. (D) The expression level of IL-1b in the TMJs of arthritic mice was only slightly above the level observed in
control mice. (E) ADAMTS-4 was highly upregulated in the arthritic joints at both the acute and chronic phases of PGIA. (F) ADAMTS-5 was only marginally upregulated in the same
joint samples. (G) MMP-3 was moderately over-expressed in the joints of animals with acute PGIA and strongly over-expressed in animals with chronic disease. (H) Conversely,
IL-1b was massively upregulated in ankle joints with acute arthritis and moderately in those with chronic inﬂammation. The most notable difference between the TMJs and ankle
joints was the very high level of IL-1b gene expression in the arthritic ankles (graph H) compared to the nearly normal levels in the TMJs (graph D) of corresponding groups of mice.
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animal model of RA. The lack of previous investigations in RA
models is surprising because the TMJ is a synovial joint, which may
become a target of autoimmune reactions in both RA and animal
models of the human disease. A signiﬁcant proportion of RA
patients experience pain in their TMJs, and analyses of synovial
ﬂuid samples clearly indicate the involvement of this joint not only
in OA, but also in RA11,24,25. In a recent study, up to 72% of newly
diagnosed RA patients were found to have TMJ involvement24. This
percentage is close to those found in studies of RA patients with
longer disease duration21,25e27 or in pediatric patients with juvenile
idiopathic arthritis28,29, a disease with RA-like features.Table II
Serum levels of pro-inﬂammatory cytokines in mice with acute or chronic PGIA and
in non-arthritic controls
Cytokine (pg/ml) Acute PGIA (N¼ 10) Chronic PGIA (N¼ 12) Control (N¼ 8)
IL-1b
Mean (CI 95%) 9.5 (7.48e11.52) 9.31 (7.88e10.74) 0 (0)
TNFa
Mean (CI 95%) 9.27 (8.01e10.53) 8.34 (6.63e10.05) 0 (0)
IL-6
Mean (CI 95%) 17.5 (14.92e20.08) 14.3 (12.75e15.31) 0 (0)
IL-17
Mean (CI 95%) 5.27 (4.06e6.48) 5.35 (4.64e6.06) 0 (0)
Serum levels of IL-1b, TNFa, IL-6, and IL-17 are expressed in pg/ml. Values of the
means and 95% CI are shown. None of these cytokines were detectable in serum
samples of control (DDA adjuvant-injected, non-arthritic) mice (last column). The
differences between mice with acute and chronic PGIA were not statistically
signiﬁcant in the serum levels of any of these cytokines (P> 0.05). N: number of
mice.We found evidence of substantial loss of PG (aggrecan) in the
mandibular cartilage of TMJs, with minimal or no local synovial
inﬂammation, inmice that developed severe inﬂammatory arthritis
in their limb joints. This ﬁnding was consistent in animals that
entered the chronic phase of arthritis (disease duration: 10 days or
longer), and aggrecan loss was occasionally associated with struc-
tural damage (ﬁbrillation or ﬁssures) in the TMJ cartilage. In the
ankle joints, severe synovitis was accompanied by chondrocyte loss
from the superﬁcial zone (pitting). Although pitting was mainly
restricted to sites where the cartilage was in contact with inﬂam-
matory cells, GAG-containing aggrecan fragments were lost from
the entire cartilage. Whereas the TMJ of mice with severe PGIA
showed evidence of structural impairment, aggrecan degradation
in mandibular cartilage was not greater, and appeared to be less
progressive, than in the inﬂamed ankle joints. This suggests that the
insults that triggered aggrecan loss and/or the response of the
joints to those stimuli could be different at these anatomically
distinct sites. Histopathologic abnormalities were not found in the
joints of age- and sex-matched control (PBS/DDA-injected) mice,
which allowed us to exclude the possibility of any age- or gender-
related association30.
Loss of PG from the TMJ cartilage of arthritic animals was
reminiscent of the changes described for cartilage in joints affected
with OA in humans or in animal models of cartilage degenera-
tion22,31. Aggrecan fragmentation could be attributed to upregula-
tion of catabolic enzymes, and we found that mRNA levels of
aggrecanases ADAMTS-4 and ADAMTS-5, and stromelysin (MMP-3)
were upregulated, and the neoepitopes generated by these
enzymes (-NITEGE and -VDIPEN) accumulated in the TMJs in
S. Ghassemi-Nejad et al. / Osteoarthritis and Cartilage 19 (2011) 458e465464animals with PGIA. These results were similar to those in the
inﬂamed ankle joints of the same animals.
Pro-inﬂammatory cytokines have a central role in aggrecanase
and MMP upregulation, and the key pro-inﬂammatory cytokine
appears to be IL-1b, although TNFa and IL-6, either directly or via
the activation of the IL-1b pathway, may also be involved in the
upregulation of aggrecanases and MMPs22,23. Chondrocytes have
been shown to produce IL-1b in response to various stimuli, and
this cytokine can activate the catabolic pathway in cartilage22,
which ultimately leads to local matrix breakdown. In support of
this, induction of chondrocyte-speciﬁc expression of the IL-1b gene
resulted in OA-like histopathological changes and dysfunction in
the TMJs of transgenic mice32. Moreover, a positive correlation was
found between the incidence of TMJ dysfunction and serum levels
of the IL-1 receptor (as a proxy for IL-1b) in RA patients33. We were
surprised to ﬁnd that the chondrocytes of the damaged mandibular
cartilage did not upregulate IL-1b expression in mice with PGIA.
However, this cytokine was markedly over-expressed in the joint
tissues of arthritic limbs of the same animals, suggesting that
exogenous IL-1b (released into the circulation from inﬂamed joints)
could be responsible for the catabolic activity of mandibular carti-
lage chondrocytes and/or surrounding synovial cells. Indeed, serum
samples from arthritic mice contained high amounts of IL-1b and
other pro-inﬂammatory cytokines, including TNFa, IL-6, and IL-17.
Notably, the serum levels of these cytokines in our arthritic mice
were comparable to concentrations found in TMJ synovial ﬂuid
samples from patients with RA or OA25,34,35.
We conclude that unlike the peripheral joints, the TMJ is not
a target of the autoimmune attack in PGIA. The OA-like cartilage
damage in the TMJs of arthritic mice is likely due to the effects of
systemic factors, such as circulating cytokines, released from
inﬂamed joints. Sustained production of these pro-inﬂammatory
cytokines (i.e., chronic disease) appeared to be necessary to induce
TMJ cartilage degradation in a consistent manner. Serum concen-
trations of pro-inﬂammatory cytokines decline at a late phase of
chronic PGIA (several weeks after disease onset)3,4. Therefore, it is
possible that the process of TMJ cartilage degradation slows down
after the “burn-out” of limb joint inﬂammation. Finally, as these
animals experience pain in their arthritic limbs, it remains to be
determined if there is pain-related overuse of the TMJ (e.g., increased
gnawing) that can contribute to cartilage damage in that joint.
In summary, we show evidence of cartilage matrix degradation
in the TMJs of mice having autoimmune inﬂammatory arthritis in
their limb joints, and propose that systemic pro-inﬂammatory
cytokines could be involved in TMJ pathology. Our results suggest
that early treatment of RA, especially with biologics, such as IL-1 or
TNF antagonists25,36e38, holds promise for the prevention of irre-
versible tissue damage in the TMJs of RA patients.
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